The Centers for Disease Control and Prevention released a ‘Dear Colleague’ letter regarding the U.S. Food and Drug Administration’s Drug Safety Communication on the potential risk of antiretroviral medication dolutegravir (DTG) associated neural tube birth defects.
CDC ‘Dear Colleague’ Letter: FDA’s Drug Safety Communication on DTG
May 23, 2018 | Kim Rodgers
About Kim Rodgers
Pronouns: She/Her
Kim Rodgers was formerly the Communications Manager at NACCHO.
Related Posts
- Adverse Childhood Experiences (ACEs)
- Behavioral Health
- Community Health
- Injury and Violence Prevention
Seeking LHD Participants for an Intersectional Data...
With support from the Centers for Disease Control and Prevention, NACCHO is...
Mar 28, 2024 | Camille Adams
Seeking LHD Participants for an Intersectional Data...
- Tools & Resources
- Community Health
- ID Featured
- Immunization
The Current Status of Measles in the US + Resources to...
This resource round-up aims to help local health departments and healthcare...
Mar 18, 2024 | Irene Halferty, Emma James, Victoria Thompson, Amy Maxson, Robin Mowson